Drugs / BAY1217389
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02366949 | Feb 2015 → Mar 2018 | — | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1217389 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02366949 ↗ |
| Known as | CPD 79 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4456085 ↗ |
| Action | Inhibit | “BAY1217389 is a potent and highly selective inhibitor of monopolar spindle 1 (MPS1) kinase activity.” NCT02366949 ↗1“Dual specificity protein kinase TTK inhibitor” CHEMBL4456085 ↗ |
| Modality | Small molecule | — CHEMBL4456085 ↗ |
| Route | Oral | “BAY1217389 will be given orally” NCT02366949 ↗ |
| Target | TTK | “Dual specificity protein kinase TTK inhibitor” CHEMBL4456085 ↗ |